New Clinical Data for Covalon’s ColActive ® Line of Patented Advanced Wound
Care Products to be Presented at SAWC Spring
Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced
that two clinical case studies demonstrating the clinical effectiveness of ColActive® Plus and ColActive®
Transfer biological matrix products will be presented at the 2018 Symposium on Advanced Wound Care Spring (“SAWC Spring”) in
Charlotte, North Carolina. In addition to the posters, Covalon will also be showcasing its full line of advanced wound care
dressings in the symposium’s exhibition hall during the three-day event.
“We are very pleased with the results of these two clinical case studies and believe that they show the advantage that the
patented ColActive technology can add to a wound care clinician’s arsenal,” said Brian Pedlar, Chief Executive Office of
Covalon.
Dr. Jeffrey Lehrman, DPM, FASPS, MAPWCA will present a clinical poster entitled A New Approach in the Management of Chronic
Diabetic Foot Ulcers: A Report on the Use of a Collagen Wound Contact Layer with Negative Pressure Wound Therapy during the
SAWC Spring – WHS Poster Gala, held on Friday, April 27th from 7:15 p.m. to 8:45 p.m.
“The combination of a collagen wound contact layer and weekly negative pressure wound therapy had a significant beneficial
effect on healing in this chronic diabetic foot ulcer,” said Dr. Lehrman. “The regimen was well tolerated and simple to administer
and offers a valuable opportunity for healing in this patient group.”
Also being presented at the SAWC Spring – WHS Poster Gala is a clinical case series entitled A New Approach in the Treatment
of Chronic Pressure Ulcers at our Center: A Report on the Use of Collagen in Saudi Arabia by Abdulkareem Iblasi, RN, MSN, and
Manju Paulose of King Saud Medical City in Riyadh, Saudi Arabia.
SAWC is the Official Meeting for Members of The Association for the Advancement of Wound Care and the leading national wound
healing conference SAWC Spring serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists,
researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes through
education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging
research findings. The conference runs from April 26-28, 2017, and Covalon will be exhibiting in booth #1311 during all exhibit
hours throughout the meeting.
Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician.
Covalon’s CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound
closure and healing in both acute and chronic wounds.
About Covalon
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the
world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies,
healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in
specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and
biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate",
"plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or
be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the
difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing
strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating
results and other risks, any of which could cause results, performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the
Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties
relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The
Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further
events or otherwise.
Covalon Technologies Ltd.
Brian Pedlar, 905-568-8400 x 233
CEO
bpedlar@covalon.com
Toll free: 1-877-711-6055
Web site:
www.covalon.com
Twitter: @covalon
View source version on businesswire.com: https://www.businesswire.com/news/home/20180426006036/en/